SHARE:   Share to Facebook Share to Twitter Share to Linked In Share via Email  

Back To Search Results

S16 - MS Characterizations and Tools for Measurement

Event Time: Monday April 24, 2017 3:30 pm to 5:30 pm
Topic(s): MS and CNS Inflammatory Disease
Director(s):
Description: A group of abstracts covering a similar topic presented in an oral format. Presentations are eight minutes in length with four minutes of question and answer. Each session concludes with 25 minutes of a discussant bringing additional context to one or more of the abstracts.
Completion Message:
CME Credits: 2
Core Competencies:

Program Speakers - Tentative

Start/End Time Title Faculty
5:05 PM - 5:30 PM Discussion Fred Lublin MD, FAAN 

Disclosures

Speaker Disclosure
Fred D. Lublin, MD, FAAN Dr. Lubin has received personal compensation for activities with Abbott, Acorda, Actelion, Allozyne, Avanir, Bayer HealthCare, Biogen Idec, Celgene, EMD Serono, Genmab, Johnson & Johnson, Medicinova, MorphoSys, Novartis, Pfizer, Questcor, Roche, Sanofi and Teva Neuros for consulting or serving on an advisory board. Dr. Lubin holds stock and/or stock options in Cognition Pharmaceuticals. Dr. Lubin has received research support from Acorda Therapeutics, Biogen Idec, Genzyme, National Institutes of Health, National MS Society, Novartis, Sanofi and Teva Neuroscience.

Abstract Presenters

Start Time Pub. Title Presenter
3:30 PM 001 Genetic descriptors of a multiple sclerosis cohort Noriko Isobe, MD
Disclosure:
Dr. Isobe has nothing to disclose.

3:42 PM 002 A Global Epidemiological Forecast of Multiple Sclerosis and Disease Subtypes Sunali Goonesekera
Disclosure:
Dr. Goonesekera has received personal compensation for activities with Decision Resources Group as an employee.

3:54 PM 003 Progressive degeneration of RNFL and GCL is seen in pediatric MS in comparison to monophasic demyelination and controls Giulia Longoni, MD
Disclosure:
Dr. Longoni has nothing to disclose.

4:06 PM 004 Sample sizes and clinical relevance of MS-specific atrophy markers: A comprehensive, unbiased, simulation-based method accounting for normal aging Christina Azevedo, MD
Disclosure:
Dr. Azevedo has received personal compensation for activities with Genzyme and Biogen.

4:18 PM 005 Ofatumumab versus teriflunomide in relapsing MS: adaptive design of two Phase 3 studies (ASCLEPIOS I and ASCLEPIOS II) Stephen L Hauser, MD
Disclosure:
Dr. Hauser serves on the scientific advisory boards for Annexon, Symbiotix, Bionure, and Molecular Stethoscope; serves on the Board of Trustees for Neurona; has received travel reimbursement and writing assistance from F. Hoffmann-La Roche Ltd. for CD20-related meetings..

4:30 PM 006 Microstructural Deterioration in Multiple Sclerosis Patients Meeting Criteria for “no evidence of disease activity”: Correlations with Clinical Variables Dylan Sperling
Disclosure:
Dr. Sperling has nothing to disclose.

4:42 PM 007 Upper Cervical Cord Area Atrophy for Clinical Trials in Multiple Sclerosis Esha Datta
Disclosure:
Dr. Datta has nothing to disclose.

4:54 PM 008 Circulating microRNAs are associated with acute inflammation in patients with multiple sclerosis. Maria Antonietta Mazzola, MD
Disclosure:
Dr. Mazzola has nothing to disclose.

Register Now

Related Courses

Saturday April 21, 2018

9:30 AM-11:30 AM
C11 Treatment of Pediatric Multiple Sclerosis in the Current Era Brenda Banwell MD, FAAN

Sunday April 22, 2018

7:00 AM-9:00 AM
C33 Multiple Sclerosis in the Trenches: Controversy and Consensus in Clinical Decision-Making Aaron Miller MD, FAAN
3:30 PM-5:30 PM
C57 Spanish: Update on MS Therapy Lilyana Amezcua MD

Tuesday April 24, 2018

7:00 AM-9:00 AM
C98 Multiple Sclerosis Overview I: Clinical Pearls John Corboy MD, FAAN
1:00 PM-3:00 PM
C108 Multiple Sclerosis Overview II: Clinical Advances Scott Newsome DO, FAAN
3:30 PM-5:30 PM
C122 Multiple Sclerosis Overview III: Basic and Translational Science Michael Racke MD

Wednesday April 25, 2018

7:00 AM-9:00 AM
C136 Multiple Sclerosis Therapy: Disease-modifying Treatment I David Jones MD
9:15 AM-11:30 AM
PL5 Frontiers in Neuroscience Plenary Session
1:00 PM-3:00 PM
C147 Multiple Sclerosis Therapy: Disease-modifying Treatment II John Rose MD, FAAN
3:30 PM-5:30 PM
C162 Multiple Sclerosis Therapy: Symptom Management Jonathan Carter MD

Thursday April 26, 2018

7:00 AM-9:00 AM
C175 Clinical Pearls in Autoimmune Neurology: Real World Cases Stacey Clardy MD, PhD
1:00 PM-3:00 PM
N5 Neuroscience in the Clinic: Treatment of Progressive Multiple Sclerosis Eric Klawiter MD,
Ellen Mowry MD, FAAN

Friday April 27, 2018

1:00 PM-3:00 PM
C224 Neuromyelitis Optica Spectrum Disorders Dean Wingerchuk MD, FAAN

MEMBER LOG IN

Forgot Password?